Cingulate (CING) Stock Price, News & Analysis

Company Overview

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Key Stats

• Today's Range: $4.42 to $4.95
• 50-Day Range: $4.39 to $11.66
• 52-Week Range: $3.20 to $11.89
• Volume: 354,282 shs
• Average Volume: 459,501 shs
• Market Capitalization: $66.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.33
• Consensus Rating: Moderate Buy

Cingulate Stock Analysis - MarketRank™

Cingulate scored higher than 57% of companies evaluated by MarketBeat, and ranked 415th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Cingulate has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cingulate has a consensus price target of $32.50, representing about 627.1% upside from its current price of $4.47.

Amount of Analyst Coverage

Cingulate has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cingulate are expected to grow in the coming year, from ($2.44) to ($1.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cingulate is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cingulate is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cingulate has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.76% of the float of Cingulate has been sold short.

Short Interest Ratio / Days to Cover

Cingulate has a short interest ratio ("days to cover") of 2.89, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cingulate has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cingulate does not currently pay a dividend.

Dividend Growth

Cingulate does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.38

News Sentiment

Cingulate has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Cingulate this week, compared to 4 articles on an average week.

Search Interest

13 people have searched for CING on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.

MarketBeat Follows

6 people have added Cingulate to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cingulate insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.33% of the stock of Cingulate is held by insiders.

Percentage Held by Institutions

41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 5/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CING
• CIK: 1862150
• Web: www.cingulate.com
• Phone: 913-942-2300
• Fax: N/A
• Employees: 20
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Cingulate: $28.33
• High Price Target: $55.00
• Low Price Target: $10.00
• Potential Upside/Downside: +520.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.45 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -365.15%
• Return on Assets: -158.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.55
• Quick Ratio: 2.55

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.40 per share
• Price / Book: 3.26

Miscellaneous

• Outstanding Shares: 13,470,000
• Free Float: 12,886,000
• Market Cap: $61.56 million
• Optionable: Not Optionable
• Beta: -0.81